Melanoma: all 3,073 studies

Page 10 of 31. Open to participants first (529), then studies with results posted, then the rest; newest registration first within each.

• Ipilimumab With or Without Talimogene Laherparepvec in Unresected MelanomaCompletedNCT01740297Phase 1/2Results posted
• LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional MutationsCompletedNCT01726738Phase 2Results posted
• Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic MelanomaCompletedNCT01721772Phase 3Results posted
• A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)CompletedNCT01721746Phase 3Results posted
• Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain MetsTerminatedNCT01721603Phase 2Results posted
• Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced MelanomaTerminatedNCT01709162Phase 2Results posted
• Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by SurgeryCompletedNCT01708941Phase 2Results posted
• Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (MK-3475-002/P08719/KEYNOTE-002)CompletedNCT01704287Phase 2Results posted
• Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for MelanomaCompletedNCT01703507Phase 1Results posted
• Interleukin-2 in Metastatic MelanomaTerminatedNCT01702896Phase 2Results posted
• Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets PtsCompletedNCT01701674Not applicableResults posted
• Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By SurgeryTerminatedNCT01701037Phase 2Results posted
• Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant MelanomaTerminatedNCT01696045Phase 2Results posted
• Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous MelanomaCompletedNCT01693068Phase 2Results posted
• Dacarbazine and Carmustine in Metastatic MelanomaTerminatedNCT01692691Phase 2Results posted
• Phase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic MelanomaTerminatedNCT01689974Phase 2Results posted
• A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic MelanomaCompletedNCT01689519Phase 3Results posted
• Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K MutationCompletedNCT01682213Phase 2Results posted
• Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).CompletedNCT01682083Phase 3Results posted
• Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced MelanomaCompletedNCT01681212Phase 2Results posted
• Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced MelanomaCompletedNCT01673854Phase 2Results posted
• A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant MelanomaCompletedNCT01667419Phase 3Results posted
• Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic MelanomaCompletedNCT01659151Phase 2Results posted
• Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal CancerTerminatedNCT01650350Phase 2Results posted
• A Study of Pegylated Interferon Alfa-2b (MK-4031) as an Adjuvant Treatment in Japanese Patients With Malignant Melanoma (MK-4031-370)TerminatedNCT01636960Phase 1Results posted
• CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks (VLA-008 CALM Ext)CompletedNCT01636882Phase 2Results posted
• A Prospective Study Using Implanted Fiducial Markers to Assess Treatment Accuracy and Esophageal Toxicity in Spinal Stereotactic Body Radiation TherapyCompletedNCT01624220Not applicableResults posted
• PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced MelanomaCompletedNCT01621490Phase 1Results posted
• An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF InhibitorCompletedNCT01619774Phase 2Results posted
• Oral N-acetylcysteine for Protection of Human Nevi Against UV-induced Oxidative Stress/Damage in VivoCompletedNCT01612221Phase 2Results posted
• Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous MelanomaCompletedNCT01597908Phase 3Results posted
• Doxycycline, Temozolomide and Ipilimumab in MelanomaTerminatedNCT01590082Phase 1/2Results posted
• Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600ETerminatedNCT01586195Phase 2Results posted
• Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal MelanomaCompletedNCT01585194Phase 2Results posted
• A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant MelanomaCompletedNCT01584648Phase 3Results posted
• A Long Term Follow up Study for Patients Who Previously Took Part in the Phase I Study IMM-101-001TerminatedNCT01559818Phase 1/2Results posted
• STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV MelanomaTerminatedNCT01551693Phase 2Results posted
• Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma PatientsTerminatedNCT01546571Phase 3Results posted
• Metronomic Therapy in Patients With Metastatic MelanomaTerminatedNCT01542255Phase 2Results posted
• Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by SurgeryTerminatedNCT01533948Phase 2Results posted
• Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or DabrafenibTerminatedNCT01519427Phase 2Results posted
• BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 MutationsTerminatedNCT01519323Phase 1Results posted
• Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg IpilimumabCompletedNCT01515189Phase 3Results posted
• BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced MelanomaCompletedNCT01512251Phase 1/2Results posted
• Trial of pIL-12 Electroporation Malignant MelanomaCompletedNCT01502293Phase 2Results posted
• RADVAX™: A STRATIFIED PHASE I/II DOSE ESCALATION TRIAL OF HYPOFRACTIONATED RADIOTHERAPY FOLLOWED BY IPILIMUMAB IN METASTATIC MELANOMACompletedNCT01497808Phase 1/2Results posted
• Yervoy With Sylatron Unresectable Stage 3 or 4 MelanomaCompletedNCT01496807Phase 1Results posted
• Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant MelanomaTerminatedNCT01495988Phase 2Results posted
• Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor CellsTerminatedNCT01495572Phase 2Results posted
• Pilot Trial to Evaluate the Effect of Vitamin D on Melanocyte BiomarkersCompletedNCT01477463Not applicableResults posted
• Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K MutationTerminatedNCT01474551Phase 2Results posted
• SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to LiverCompletedNCT01473004Phase 2Results posted
• Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal MelanomaTerminatedNCT01471054Phase 2Results posted
• Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic MelanomaTerminatedNCT01468818Phase 2Results posted
• Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant MelanomaCompletedNCT01462773Phase 1Results posted
• Recombinant Interferon Alfa-2b in Treating Patients With MelanomaCompletedNCT01460875Not applicableResults posted
• Phase II FANG™ in Advanced MelanomaTerminatedNCT01453361Phase 2Results posted
• Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation TherapyCompletedNCT01449279Phase 2Results posted
• Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LCTerminatedNCT01437605Phase 2Results posted
• A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant MelanomaCompletedNCT01436656Phase 1Results posted
• Study to Assess Safety and Immune Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCICompletedNCT01425749Early Phase 1Results posted
• Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic MelanomaCompletedNCT01425008Phase 1Results posted
• Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma.Active, not recruitingNCT01416831Phase 2Results posted
• Cixutumumab in Treating Patients With Metastatic Melanoma of the EyeCompletedNCT01413191Phase 2Results posted
• Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)TerminatedNCT01400451Phase 1Results posted
• Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat MelanomaCompletedNCT01397708Phase 1/2Results posted
• Does the Aid of MelaFind Affect Clinical Management DecisionsCompletedNCT01387581Results posted
• A Study of Vemurafenib in Metastatic Melanoma Participants With Brain MetastasesCompletedNCT01378975Phase 2Results posted
• Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic MelanomaTerminatedNCT01369888Phase 1/2Results posted
• Modified Tumor Infiltrating Lymphocytes for Metastatic MelanomaTerminatedNCT01369875Phase 2Results posted
• An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in MelanomaCompletedNCT01368276Phase 3Results posted
• Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant MelanomaCompletedNCT01359956Phase 3Results posted
• Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic MelanomaTerminatedNCT01350401Phase 1/2Results posted
• Efficacy Study of Pharmacokinetic(PK)/Pharmacodynamic(PD) Relationship of Monotherapy MORAb-004 in Metastatic MelanomaCompletedNCT01335009Phase 2Results posted
• Individualized Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By SurgeryCompletedNCT01328535Phase 2Results posted
• Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The ExtremityCompletedNCT01323517Phase 2Results posted
• Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant MelanomaCompletedNCT01321437Phase 2Results posted
• A Phase II Study of Single Agent MEK162 in Patients With Advanced MelanomaCompletedNCT01320085Phase 2Results posted
• Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...CompletedNCT01319565Phase 2Results posted
• Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV MelanomaTerminatedNCT01316692Phase 2Results posted
• A Clinical Study, to Evaluate the Safety and Tolerability of Intradermal IMM-101 in Adult Melanoma Cancer PatientsCompletedNCT01308762Phase 1Results posted
• Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma PatientsTerminatedNCT01308294Phase 1/2Results posted
• Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic MelanomaTerminatedNCT01307618Phase 2Results posted
• A Study of Vemurafenib in Participants With Metastatic MelanomaCompletedNCT01307397Phase 3Results posted
• A Study Of PF-05082566 As A Single Agent And In Combination With RituximabCompletedNCT01307267Phase 1Results posted
• Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001)CompletedNCT01295827Phase 1Results posted
• Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver MetastasesCompletedNCT01290536Phase 2Results posted
• Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by SurgeryActive, not recruitingNCT01274338Phase 3Results posted
• MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered LymphocytesTerminatedNCT01273181Phase 1/2Results posted
• Drosophila-generated CTLTerminatedNCT01271907Phase 2Results posted
• A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic MelanomaCompletedNCT01271803Phase 1Results posted
• A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma to the BrainCompletedNCT01266967Phase 2Results posted
• High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCICompletedNCT01266603Phase 2Results posted
• A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic MelanomaCompletedNCT01264380Phase 1Results posted
• Lapatinib in Stage IV Melanoma With ERBB4 MutationsTerminatedNCT01264081Phase 2Results posted
• Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by SurgeryCompletedNCT01258855Phase 2Results posted
• Docetaxel With or Without AZD6244 in MelanomaCompletedNCT01256359Phase 2Results posted
• A Study of RO5185426 in Previously Treated Melanoma Patients With Brain MetastasesCompletedNCT01253564Phase 2Results posted
• Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)CompletedNCT01251978Phase 2Results posted
• A Study of RO5185426 in Patients With Metastatic MelanomaCompletedNCT01248936Phase 2Results posted

← Melanoma overview